Can we tame the monster?BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7558.0-f (Published 06 July 2006) Cite this as: BMJ 2006;333:0-f
- Fiona Godlee, editor (email@example.com)
What can we learn from the New England Journal of Medicine's correction last week of its study on rofecoxib (BMJ 2006;333: 12, 1 Jul)? The simple message is that increased cardiovascular risks were visible as early as four months into treatment, rather than the 18 months that Merck had claimed. But rofecoxib was withdrawn two years ago, so why all the fuss?
Well, reputations are at stake. The journal wants to show that it had made no mistakes in peer reviewing the study. And Merck, having already incurred financial loss, needs to protect its …